Tumor-associated antigen-Major Histocompatibility Complex (TAA-MHC complex) (TAA-MHC complex)

The Tumor-associated antigen-Major Histocompatibility Complex (TAA-MHC complex) is a multi-component molecular assembly essential for the initiation of an anti-tumor immune response. Dendritic cells (DCs) function as professional antigen-presenting cells by capturing tumor-associated antigens (TAAs), processing them into peptides, and displaying them on Major Histocompatibility Complex (MHC) Class I and II molecules (Rock et al., 2016, Chemical Reviews). This presentation allows for the specific recognition of tumor cells by T-cell receptors (TCRs) on the surface of CD8+ cytotoxic T lymphocytes and CD4+ helper T cells (StatPearls, 2023). In therapeutic contexts, such as dendritic cell vaccines, patient-derived DCs are loaded with TAAs ex vivo to enhance this presentation and overcome tumor-induced immunosuppression (Anguille et al., 2014, Pharmacological Reviews). The most prominent example of a drug utilizing this mechanism is Sipuleucel-T, which is used to treat metastatic castration-resistant prostate cancer by targeting prostatic acid phosphatase (Kantoff et al., 2010, NEJM). Challenges associated with this target include the identification of highly specific antigens to avoid off-target autoimmunity and the requirement for personalized manufacturing processes (PubMed, PMC4007132).

Other names

Tumor antigen-HLA complexDendritic cell-presented antigensMHC-peptide complexAntigen-MHC-TCR complexTAA-HLA complex

Dendritic cells present tumor-derived peptides via MHC molecules to T-cell receptors, leading to the activation and proliferation of tumor-specific CD4+ and CD8+ T cells.